Diabetomics, Inc. products

The first and only point-of-care saliva test for diabetes monitoring.

The first and only point-of-care tests for early detection of type-1 diabetes and LADA (Latent Autoimmune Diabetes in Adults)

The Lumella® Test, The New Point-of-Care Blood Test Helps in Early Detection of Preeclampsia; The Lumella® test estimates the concentration of Glycosylated Fibronectin, a new pregnancy specific biomarker to accurately assess the risk of preeclampsia. The Lumella® test requires a simple finger stick and can be performed in physician’s office/clinic in the first, second, or third trimesters, between 13 to 37 weeks of gestation.

First rapid point-of care test for detection of rheumatoid arthritis; Non-invasive oral fluid or finger stick sample; Results in 15 minutes; ACA rapid, point-of-care test for assessment of anti-citrullinated human serum albumin (HSA) autoantibodies (ACAs) and Anti-citrullinated peptides auto antibodies (ACCP)* for screening and diagnosis of RA and potential companion diagnostic role with DARD’s